SCHEMBL23920262

SCHEMBL23920262

O=C(N[C@H]1CC[C@H](NCc2ccc3cc(Cl)ccc3n2)CC1)C1Cc2ccncc2O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.38
▸ HDAC2 Q92769 2/20 0.38
▸ GLS O94925 2/20 0.36
▸ NAMPT P43490 4/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ P2RX7 Q99572 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ C3AR1 Q16581 1/20 0.35
▸ SMYD3 Q9H7B4 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ KDM4C Q9H3R0 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ PTGES O14684 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23920267 0.86 ATF4 (0.42) GLSNAMPTCYP1A2CYP3A4CYP2C9
SCHEMBL23920263 0.80 GLS (0.51) GLSNAMPTCYP1A2CYP3A4CYP2C9
SCHEMBL23920375 0.77 HRH4 (0.42) NAMPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL23920219 0.76 CHRNA7 (0.47) HDAC1HDAC2NAMPTCYP1A2CYP3A4
SCHEMBL23920380 0.75 MAOB (0.41) GLSCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL23920604 0.74 NPY1R (0.50) MEN1KMT2AALDH1A1
SCHEMBL23920610 0.74 NPY1R (0.50) MEN1KMT2AALDH1A1
SCHEMBL23920621 0.69 KMT2A (0.58) GLSCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL23920319 0.68 HRH1 (0.47) —
SCHEMBL21050182 0.67 ATF4 (0.58) NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2023-02-16 — — US disclosed
US-11230542-B2 Inhibitors of integrated stress response pathway Praxis Biotech LLC (US) 2022-01-25 — — US disclosed
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2021-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 HDAC1 937/4885HDAC2 805/4885GLS 319/4885
US-11230542-B2 Inhibitors of integrated stress response pathway ATF4, DDIT3, ATF1 HDAC1 937/4885HDAC2 805/4885GLS 319/4885
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 HDAC1 937/4885HDAC2 805/4885GLS 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback